menu

Licensing

Our lead therapeutic candidate, NJA-730, is an oligonucleotide drug targeting CD40 that is currently being evaluated in a Phase 1 first-in-human clinical study in healthy volunteers. The compound is initially being developed as a potential treatment for graft-versus-host disease (GVHD), though we believe there are numerous inflammatory immunoreactive conditions against which the compound may hold therapeutic promise.

If you are interested in exploring licensing opportunities for NJA-730 in GVHD or non-GVHD indications such as organ transplantation and various inflammatory immunoreactive conditions, please contact us at: Akihiko Watanabe, Ph.D. Vice President, Research Innovations & BD. e-mail: a.watanabe@napajen.com /cell: +81-70-4514-7667